<Li> OX--oxaliplatin (Eloxatin), a platinum - based antineoplastic agent, which inhibits DNA repair and / or DNA synthesis; </Li> <Li> IRI--irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating . </Li> <P> It is usually given with bevacizumab, unlike FOLFIRINOX for treatment of advanced pancreatic cancer . Also, the doses (Day 1: irinotecan 165 mg / m2 IV, plus oxaliplatin 85 mg / m2 IV; Day 1: leucovorin 400 mg / m2; Days 1--3: fluorouracil 1,600 mg / m2 / day × 2 days (total 3,200 mg / m2 over 48 hours) continuous infusion starting on day 1; Day 1: bevacizumab 5 mg / kg IV; repeat cycle every 2 weeks) are slightly dissimilar to FOLFIRINOX . </P> <P> Upfront FOLFOXIRI with bevacizumab can be followed by fluoropyrimidine with bevacizumab maintenance . </P>

Initial therapy with folfoxiri and bevacizumab for metastatic colorectal cancer